Standard BioTools to merge with Treeline in $2.5B deal; shareholders diluted to 16% stake

Filed June 8, 2026 · Period ending June 6, 2026 · ~1 min read

Key Changes

• high

  Standard BioTools agrees to all-stock merger with Treeline Biosciences valued at $2.5B. Existing shareholders will own only ~16% of combined company post-close, with Treeline shareholders controlling 84%—representing massive dilution.

  Item 1.01: Merger Agreement verify on EDGAR →
• high

  Treeline executives will lead combined company: 10 of 12 board seats go to Treeline, and Treeline's CEO, CSO, and CFO will assume all C-suite roles. Standard BioTools leadership effectively replaced.

  Item 1.01: Leadership verify on EDGAR →
• high

  Standard BioTools must sell or wind down its entire legacy business (mass cytometry and microfluidics). If no buyer found by registration effective date, company will begin shutdown of current operations.

  Item 1.01: Legacy Business verify on EDGAR →